Paper Review Records
All Paper Review Records
12 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
70
days
Late acquisition of BCR::ABL1 during clonal evolution of SAMD9- associated MDS with phenotypic shift from AML to B-ALL
AuthorsYusuke Nakata; Anna Hiratsuka; Takeshi Yoroidaka; Wakana Takahashi; Itaru Nishikawa; Masataka Sakashita; Shinya Yamada; Hiroki Mizumaki; Akiyo Yoshida; Tatsuya Imi; Hiroyuki Maruyama; Hiroyuki Takamatsu; Kohei Hosokawa; Yasuhito Nannya; Seishi Ogawa; Toshihiro Miyamoto
Affiliations1. Department of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan; 2. Division of Hematology, Keiju Kanazawa Hospital, Kanazawa, Japan; 3. Division of Hematopoietic Disease Control, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; 4. Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
119
days
Improved post-transplant outcomes following inotuzumab ozogamicin-based salvage therapy in relapsed/refractory B-ALL: a real-world retrospective study
AuthorsRyo Koizumi; Shinsuke Takagi; Aya Nishida; Mika Kuno; Rikako Tabata; Otoya Watanabe; Kyosuke Yamaguchi; Kosei Kageyama; Daisuke Kaji; Yuki Taya; Kazuya Ishiwata; Hisashi Yamamoto; Akiko Masuda; Yukako Koike; Hideki Araoka; Yuki Asano-Mori; Go Yamamoto; Atsushi Wake; Shuichi Taniguchi; Naoyuki Uchida
Affiliations1. Department of Hematology, Toranomon Hospital, Tokyo, Japan; 2. Center for Long-Term Follow-Up After Hematopoietic Cell Transplantation, Toranomon Hospital, Tokyo, Japan; 3. Okinaka Memorial Institute for Medical Research, Tokyo, Japan; 4. Department of Hematology, Toranomon Hospital Kajigaya, Kawasaki, Japan; 5. Department of Transfusion and Cellular Therapy, Toranomon Hospital, Tokyo, Japan; 6. Center for Cellular Therapy, Toranomon Hospital, Tokyo, Japan; 7. Department of Clinical Laboratory, Toranomon Hospital, Tokyo, Japan
113
days
Gene editing of hematopoietic stem cells: applications and advances
AuthorsQiuyang Li; Hongxia Wang; Yuqin He; Genyue Hong; Guoxiu Bao
Affiliations1. Department of Hematology, Dali Bai Autonomous Prefecture People’s Hospital in Dali, Dali City, China
68
days
Long-term treatment-free remission in CML after early dasatinib discontinuation due to interstitial pneumonitis
AuthorsMakoto Kashimura; Yuki Fujioka; Yong-Mei Guo; Teruko Takahashi; Keiichi Moriya; Naoto Takahashi
Affiliations1. Division of Hematology, Shinmatsudo Central General Hospital, Matsudo, Japan; 2. Division of Central Laboratory, Akita University Hospital, Akita, Japan; 3. Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan
205
days
Efficacy and safety of maribavir in Japanese patients with post-transplant cytomegalovirus infections: a phase III study
AuthorsYoshinobu Kanda; Katsuto Takenaka; Tatsu Tanabe; Kazuya Omoto; Kei Kamimura; Kentaro Kudou; Masato Kaneko
Affiliations1. Division of Hematology, Jichi Medical University, Shimotsuke, Japan; 2. Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University, Matsuyama, Japan; 3. Department of Kidney Transplant Surgery, Sapporo City General Hospital, Sapporo, Japan; 4. Yochomachi Clinic, Tokyo, Japan; 5. Takeda Pharmaceutical Company Limited, Osaka, Japan
71
days
TFH phenotype and response to tucidinostat in relapsed/refractory PTCL: analysis of patients from a phase IIb trial
AuthorsKoji Izutsu; Ayumi Fujimoto; Shinya Rai; Dai Maruyama; Ken Ohmachi; Akihiko Yokohama; Kunihiro Tsukasaki; Toshiki Uchida; Junya Kuroda; Ilseung Choi; Michihiro Hidaka; Jun Ando; Takashi Sakamoto; Hisashi Kato; Hironobu Minami; Shinichiro Yoshida; Matsuo Yamamoto; Mireille Gillings; Hiroshi Onogi; Kengo Takeuchi
Affiliations1. Department of Hematology, National Cancer Center Hospital, Tokyo, Japan; 2. Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; 3. Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; 4. Department of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Sakai, Japan; 5. Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; 6. Department of Hematology and Oncology, Tokai University Hospital, Isehara, Japan; 7. Department of Hematology, Gunma University Hospital, Maebashi, Japan; 8. Department of Hematology, International Medical Center, Saitama Medical University, Hidaka, Japan; 9. Department of Hematology and Oncology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan; 10. Division of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan; 11. Department of Hematology and Cell Therapy, NHO Kyushu Cancer Center, Fukuoka, Japan; 12. Department of Hematology, NHO Kumamoto Medical Center, Kumamoto, Japan; 13. Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan; 14. Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; 15. Department of Hematology and Oncology, The University of Osaka Graduate School of Medicine, Suita, Japan; 16. Division of Medical Oncology and Hematology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan; 17. Department of Hematology, NHO Nagasaki Medical Center, Omura, Japan; 18. Clinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan; 19. HUYA BIO International, LLC, San Diego, USA; 20. Huya Japan GK, Tokyo, Japan
98
days
NPM1-rearranged AML: clinical features, molecular pathogenesis, and therapeutic perspectives
AuthorsYuko Shimosato; Susumu Goyama
Affiliations1. Division of Molecular Oncology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Minato-ku, Japan
65
days
Role of cross-mixing tests in differentiating etiologies of prolonged aPTT: a single-center retrospective study
AuthorsNahomi Suita; Aozora Kanemaru; Noriko Komori; Koichi Nitta; Haruyuki Fujita; Hiroshi Kawabata
Affiliations1. Department of Clinical Laboratory, NHO Kyoto Medical Center, Kyoto, Japan; 2. Department of Hematology, NHO Kyoto Medical Center, Kyoto, Japan
165
days
Clinical implications of minimal residual disease monitoring in multiple myeloma
AuthorsTakeshi Yoroidaka
Affiliations1. Department of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan
62
days
Effectiveness and tolerability of switching from 20% subcutaneous immunoglobulin to hyaluronidase-facilitated subcutaneous immunoglobulin 10% in the same patients with secondary hypogammaglobulinemia
AuthorsYoshinori Hashimoto; Saaya Hosoda; Hiromi Omura; Takayuki Tanaka
Affiliations1. Department of Hematology, Tottori Prefectural Central Hospital, Tottori, Japan
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days